Advertisement

Schizophrenia

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

Schizophrenia
Schizophrenia
FDA Approves New Dosing Duration for Aristada
06/06/2017
Aristada recently received approval from the US Food and Drug Administration for a new and shorter dosing regimen, providing more options to patients and health care providers.
06/06/2017